Grewal, MD, assistant professor at the Winship Cancer Institute at Emory University discusses the significant and concerning ...

Daraxonrasib received FDA orphan drug designation for pancreatic cancer, targeting RAS mutations in pancreatic ductal ...

A new analysis reveals unique symptom burdens and quality of life challenges in younger patients with neuroendocrine tumors, ...

Combinations of androgen deprivation therapy (ADT) and androgen receptor pathway inhibitors (ARPIs) are the accepted ...

These cases illustrate scenarios where final pathology often reveals a higher risk of recurrence than anticipated, requiring ...

Marshall emphasizes the complexity of staying updated with various cancers and treatments, the diverse knowledge bases among event participants, and the importance of understanding data application ...

The FDA has granted fast track designation to JSKN003, a biparatopic HER2-targeting antibody-drug conjugate (ADC), for the treatment of platinum-resistant ovarian cancer (PROC), regardless of human ...

GLP-1 receptor agonists show promise in treating various chronic conditions, but potential risks and unanswered questions remain for care of patients with NETs.

Nirogacestat significantly improved progression-free survival and objective response rates in desmoid tumor patients compared ...

Early-onset NETs are rising, especially among racial minorities, with significant sociodemographic shifts observed in younger patients. Younger NET patients experience a higher symptom burden, ...

As the incidence of obesity continues to rise nationally and globally, a new observational study published in Cancer reports ...

The FDA has granted breakthrough therapy designation to zenocutuzumab (Bizengri) for the treatment of patients with advanced ...